Maynard Um
-
-
-
-
-
-
-
Kiora Pharmaceuticals reports KIO-300 reduced seizure activity in lab model
-
-
-
-
-
-
-
Kiora Pharmaceuticals closes $24 million private placement
-
-
-
-
-
-
-
Kiora Pharmaceuticals adds retinal disease expert to advisory board
-
-
-
-
-
-
-
Kiora Pharmaceuticals joins RARE-X Vision Consortium for rare eye diseases
-
-
-
-
-
-
-
Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease
-
-
-
-
-
-
-
Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027
-
-
-
-
-
-
-
Kiora Pharmaceuticals (KPRX) Misses Q3 EPS by 81c
-
448,590 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

